Limited access to CD4 + T-cell count monitoring and opportunistic infection management complicates treatment, highlighting the importance of integrated mpox–HIV care models and vaccine safety studies for people with weakened immune systems. The gene discussed is CD4; the disease is Opportunistic infection.